Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

443 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group. Costentin CE, et al. Among authors: larrey d. Gastroenterology. 2018 Aug;155(2):431-442.e10. doi: 10.1053/j.gastro.2018.04.027. Epub 2018 May 3. Gastroenterology. 2018. PMID: 29729258 Free article.
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.
Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder SD, Zoulim F, Botros I, Flaherty JF, Jump B, Op den Brouw ML, van Troostenburg A, Ramroth H; ReCoRd (Retrospective, Cohort, Renal, Viread) Investigators' Group. Lampertico P, et al. Aliment Pharmacol Ther. 2020 Aug;52(3):500-512. doi: 10.1111/apt.15901. Epub 2020 Jun 25. Aliment Pharmacol Ther. 2020. PMID: 32583915 Free PMC article.
Socioeconomic Deprivation Weighs Heavily on Liver Fibrosis and Mortality After Hepatitis C Cure (ANRS CO22 Hepather).
Barré T, Parlati L, Bourlière M, Ramier C, Marcellin F, Protopopescu C, Di Beo V, Moins C, Dorival C, Nicol J, Zucman-Rossi J, Mathurin P, Larrey D, Boursier J, Carrat F, Carrieri P; ANRS/AFEF Hepather Study group. Barré T, et al. Among authors: larrey d. J Viral Hepat. 2024 Dec;31(12):830-846. doi: 10.1111/jvh.14006. Epub 2024 Sep 10. J Viral Hepat. 2024. PMID: 39252600
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.
Cornberg M, Hüppe D, Sarrazin C, Ahumada A, Jorquera Plaza F, Mariño Z, Otano JIU, Conway B, Myles L, Ramji A, Abergel A, Asselah T, Larrey D, Aghemo A, Andreoni M, Gasbarrini A, Lampertico P, Persico M, Villa E, Carmiel M, Chodick G, Weil C, Bhagat A, Bondin M, Butrymowicz I, Song Y, Semizarov D, Sonparote S, Llamas C; CREST Study Group. Cornberg M, et al. Among authors: larrey d. Adv Ther. 2024 Dec;41(12):4669-4682. doi: 10.1007/s12325-024-02996-6. Epub 2024 Oct 29. Adv Ther. 2024. PMID: 39470876
Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM.
Hountondji L, Faure S, Palassin P, Viel PWD, Dupuy M, Larrey D, Lamoureux A, Coustal C, Pureur D, Lesage C, Assenat É, Rivière B, Faillie JL, Quantin X, Pageaux GP, Maria ATJ, Meunier L. Hountondji L, et al. Among authors: larrey d. Aliment Pharmacol Ther. 2024 Dec;60(11-12):1561-1572. doi: 10.1111/apt.18276. Epub 2024 Sep 24. Aliment Pharmacol Ther. 2024. PMID: 39315730 Free PMC article.
Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study.
Nicolas C, Domas Q, Pol S, Bardou-Jacquet E, Loustaud-Ratti V, Métivier S, Asselah T, Thabut D, Bourlière M, Mathurin P, Foucher J, Larrey D, Varaut A, Alric L, Bailly F, Muti L, Buchard B, Abergel A. Nicolas C, et al. Among authors: larrey d. Liver Int. 2024 Nov 12. doi: 10.1111/liv.16158. Online ahead of print. Liver Int. 2024. PMID: 39530494
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. Harrison SA, et al. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000. N Engl J Med. 2024. PMID: 38324483 Clinical Trial.
443 results